Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: The impact on clinical outcome and future treatment options

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 10, 2013, Pages 1295-1301

  Hassing, R J ^a   Goessens, W H F ^a   Mevius, D J ^b,c   Van Pelt, W ^d   Mouton, J W ^e   Verbon, A ^a   Van Genderen, P J ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Harbour Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SCHOOL CHILD; SMALL INTESTINE PERFORATION; SUDDEN DEAFNESS; TREATMENT OUTCOME; TYPHOID FEVER;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BLOOD; CHILD; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PARATYPHOID FEVER; RETROSPECTIVE STUDIES; SALMONELLA PARATYPHI A; SALMONELLA TYPHI; TRAVEL; TREATMENT OUTCOME; TYPHOID FEVER; YOUNG ADULT;

EID: 84890549563     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1878-9     Document Type: Article

References (29)

1. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED (2008) Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 136(4):436-448. doi: 10.1017/S0950268807009338
2. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ (2002) Typhoid fever. N Engl J Med 347(22):1770-1782. doi: 10.1056/NEJMra020201
3. Hume S, Schulz T, Vinton P, Korman T, Torresi J (2009) Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience. Eur J Clin Microbiol Infect Dis 28(8):963-970. doi: 10.1007/s10096-009-0732-6
4. Slinger R, Desjardins M, McCarthy AE, Ramotar K, Jessamine P, Guibord C, Toye B (2004) Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 4:36
5. Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ (2007) Cases of typhoid fever imported into England, Scotland and Wales (2000-2003). Trans R Soc Trop Med Hyg 101(4):398-404. doi: 10.1016/j.trstmh.2006.07.005
6. Piersma D, Overbosch D, Petit P, van Genderen PJ (2004) Protracted fever after a journey to India and Nepal: a case of persistent Salmonella paratyphi infection. J Travel Med 11(4):257-259
7. Jensenius M, Han PV, Schlagenhauf P, Schwartz E, Parola P, Castelli F, von Sonnenburg F, Loutan L, Leder K, Freedman DO; GeoSentinel Surveillance Network (2013) Acute and potentially life-threatening tropical diseases in Western travelers - a GeoSentinel Multicenter Study, 1996-2011. Am J Trop Med Hyg 88(2):397-404. doi: 10.4269/ajtmh.12-0551
8. Menezes GA, Harish BN, Khan MA, Goessens WH, Hays JP (2012) Antimicrobial resistance trends in blood culture positive Salmonella Typhi isolates from Pondicherry, India, 2005-2009. Clin Microbiol Infect 18(3):239-245. doi: 10.1111/j.1469-0691.2011.03546.x
9. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A (2005) Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 5:37. doi: 10.1186/1471-2334-5- 37
10. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD (2008) Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 102(1):91-95. doi: 10.1016/j.trstmh.2007.10.003
11. Parry CM (2004) The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 98(7):413-422. doi: 10.1016/j.trstmh.2003.10.014
12. Hassing RJ, Menezes GA, van Pelt W, Petit PL, van Genderen PJ, Goessens WH (2011) Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A isolates from travellers to Southeast Asia. Int J Antimicrob Agents 37(3):240-243. doi: 10.1016/j.ijantimicag.2010.10.026
13. Pfeifer Y, Matten J, Rabsch W (2009) Salmonella enterica serovar Typhi with CTX-M beta-lactamase, Germany. Emerg Infect Dis 15(9):1533-1535. doi: 10.3201/eid1509.090567
14. Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, Mulder JA, Fijen CA, Maten W, Vandenbroucke-Grauls CM, Savelkoul PH (2008) Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J Clin Microbiol 46(8):2794-2795. doi: 10.1128/JCM.00676-08
15. Rotimi VO, Jamal W, Pal T, Sovenned A, Albert MJ (2008) Emergence of CTX-M-15 type extended-spectrum beta-lactamase-producing Salmonella spp. in Kuwait and the United Arab Emirates. J Med Microbiol 57(Pt 7):881-886. doi: 10.1099/jmm.0.47509-0
16. Gokul BN, Menezes GA, Harish BN (2010) ACC-1 beta-Lactamase-producing Salmonella enterica Serovar Typhi, India. Emerg Infect Dis 16(7):1170-1171. doi: 10.3201/eid1607.091643
17. Bijkerk P (2011) Veranderingen in de epidemiologie. Staat van Infectieziekten in Nederland. Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
18. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37(5):1073-1081
19. Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG (2005) Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 49(5):1775-1781. doi: 10.1128/AAC.49.5.1775-1781.2005
20. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55(5):601-607. doi: 10.1093/jac/dki079
21. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44(1):79-86. doi: 10.1086/510079
22. van Wolfswinkel ME, Lahri H, Wismans PJ, Petit PL, van Genderen PJ (2009) Early small bowel perforation and cochleovestibular impairment as rare complications of typhoid fever. Travel Med Infect Dis 7(5):265-268. doi: 10.1016/j.tmaid.2009.06.003
23. Stahlmann R, Lode H (1999) Toxicity of quinolones. Drugs 58(Suppl 2):37-42
24. Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, Doan CD, Nguyen TB, Duong TL, Luong BH, Nguyen TB, Nguyen TA, Pham ND, Mai NL, Phan VB, Vo AH, Nguyen VM, Tran TT, Tran TC, Schultsz C, Dunstan SJ, Stepniewska K, Campbell JI, To SD, Basnyat B, Nguyen VV, Nguyen VS, Nguyen TC, Tran TH, Farrar J (2008) A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 3(5):e2188. doi: 10.1371/journal.pone.0002188
25. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, Yadav B, Stepniewska K, Campbell JI, Dolecek C, Farrar JJ, Basnyat B (2007) An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One 2(6):e542. doi: 10.1371/journal.pone. 0000542
26. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR (2008) Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 23(3):422-430. doi: 10.1016/j.jcrc.2007.11.011
27. Haeseker MB, Dukers-Muijrers NH, Hoebe CJ, Bruggeman CA, Cals JW, Verbon A (2012) Trends in antibiotic prescribing in adults in Dutch general practice. PLoS One 7(12):e51860. doi: 10.1371/journal.pone.0051860
28. DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58(3):337-344. doi: 10.1016/j. diagmicrobio.2007.01.004
29. Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141-160. doi: 10.1111/j.1469-0691.2011.03703.x